Overview

LMN-201 for Prevention of C. Difficile Infection Recurrence

Status:
Not yet recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This is a multisite study to evaluate the safety, tolerability, and efficacy of LMN-201 in participants recently diagnosed with CDI who are scheduled to receive or are receiving SOC antibiotic therapy against C. difficile.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Lumen Bioscience, Inc.